Immunofluorescence-based reclassification of idiopathic membranoproliferative glomerulonephritis: Insights from a single-center cohort

Table 3 Renal function comparison between immune complex-mediated membranoproliferative glomerulonephritis and complement-mediated membranoproliferative glomerulonephritis at baseline and 36 months, including outcomes, median (interquartile rage)/n (%)/mean ± SD

	IC-MPGN (n = 100)	C-MPGN (n = 28)	P value
At presentation
Serum creatinine (mg/dL)	2.25 (1.6-3.7)	2.55 (1.6-5.3)	0.537
eGFR (mL/minute/1.73 m2)	62.6 (40-108)	57 (20-99.8)	0.208
Serum albumin (g/dL)	2.40 ± 0.60	2.68 ± 0.70	0.036
Patients followed for 36 months	88 (88)	24 (85.7)
Serum creatinine (mg/dL)	1.5 (0.80-7.0)	1.8 (1.0-7.7)	0.507
eGFR (mL/minute/1.73 m2)	72.2 (14-118)	68 (22-95.2)	0.62
Serum albumin (g/dL)	3.17 ± 0.76	3.32 ± 0.79	0.385
Final outcomes			0.555
CR	27 (27)	5 (17.85)
PR	35 (35)	12 (42.85)
ESKD	26 (26)	7 (25)
Lost to FU	8 (8)	4 (14.2)	0.32
Overall mortality	4 (4)	0 (0)	0.24
Renal survival	62 (62)	17(60.7)	0.62

Continuous variables were compared using the Mann-Whitney U test (or Student’s t-test for normally distributed data). Categorical variables were analyzed using χ² or Fisher’s exact test, as appropriate. eGFR: Estimated glomerular filtration rate; CR: Complete remission; PR: Partial remission; ESKD: End-stage kidney disease; FU: Follow-up; IC-MPGN: Immune complex-mediated membranoproliferative glomerulonephritis; C-MPGN: Complement-mediated membranoproliferative glomerulonephritis.